Table 1.
Treatment Duration and Time to Peak FEV1 Measure
| Mean, days ± SD | Median, days | Range, days (min - max) | Interquartile Range, days | |
|---|---|---|---|---|
|
Antibiotic Treatment Duration |
||||
| All patients (n = 95) |
12.6 ± 3.2 |
13 |
23 (4 - 27) |
3 |
| ceftaz/tobra treated (n = 50) |
12.5 ± 2.8 |
12.5 |
12 (4 - 16) |
3.75 |
| mero/tobra treated (n = 45) |
12.8 ± 3.6 |
13 |
21 (6 - 27) |
3 |
| FEV1 ≥ 70% predicted (n = 11) |
11.9 ± 2.4 |
12 |
8 (7 - 15) |
3 |
| FEV1 40% - 69% predicted (n = 46) |
12.3 ± 2.8 |
13 |
15 (6 - 21) |
3 |
| FEV1 < 40% predicted (n = 38) |
13.2 ± 3.8 |
14 |
23 (4 - 27) |
3 |
|
Time to Peak FEV1 Measure |
||||
| All patients |
8.7 ± 4.0 |
10 |
19 (0 - 19) |
6.5 |
| ceftaz/tobra treated |
8.9 ± 4.0 |
10 |
15 (1 - 16) |
6.75 |
| mero/tobra treated |
8.5 ± 4.3 |
9 |
19 (0 - 19) |
5 |
| FEV1 ≥ 70% predicted |
7.9 ± 3.3 |
7 |
12 (4 - 15) |
5 |
| FEV1 40% - 69% predicted |
8.0 ± 4.2 |
9.5 |
15 (0 - 15) |
6 |
| FEV1 < 40% predicted | 9.9 ± 3.6 | 10 | 16 (3 - 19) | 4.75 |